Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a randomized, double-blind, placebo-controlled, phase I clinical study to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of JS016 (anti-SARS-CoV-2 monoclonal antibody) injection in Chinese healthy subjects after intravenous infusion of single dose.Eligible patients will be injection JS016 (anti-SARS-CoV-2 monoclonal antibody)
Description: Any adverse event, serious adverse event (SAE) occurred during the clinical study, including clinical symptoms and abnormal vital signs, abnormal laboratory tests (complete blood cell count, serum chemistry, routine urinalysis, coagulation function, etc.) and 12-lead ECGs will be observed for all the subjects, the their clinical manifestations and features, severity, time to onset, end time, therapeutic measures and outcomes will be recorded, and the correlation of the adverse events with the investigational product will be judged
Measure: Correlation of adverse events with the investigational product Time: 12 WeeksDescription: Area under the curve from the time of dosing to the last measurable concentration time t (AUC0-last);
Measure: Primary pharmacokinetic variables Time: 12 WeeksDescription: Maximum concentration (Cmax);
Measure: Primary pharmacokinetic variables Time: 12 WeeksDescription: Mean residence time (MRT)
Measure: Primary pharmacokinetic variables Time: 12 WeeksDescription: Terminal half life (t1/2);
Measure: Primary pharmacokinetic variables Time: 12 WeeksDescription: Area under the analyte concentration-time curve from time 0 and extrapolated to infinite time (AUC0-∞);
Measure: pharmacokinetic Time: 12 WeeksDescription: Time to maximum concentration (Tmax);
Measure: pharmacokinetic Time: 12 WeeksDescription: Clearance (CL);
Measure: pharmacokinetic Time: 12 WeeksDescription: Apparent terminal elimination rate constant (λz)
Measure: pharmacokinetic Time: 12 WeeksDescription: Apparent volume of distribution (Vd)
Measure: pharmacokinetic Time: 12 WeeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports